Agilent announces ngs assay for comprehensive genomic profiling (cgp) for advancing precision oncology

Santa clara, calif.--(business wire)--agilent technologies inc. (nyse: a) today announced the launch of the agilent sureselect cancer cgp assay designed for somatic variant profiling for a broad range of solid tumor types. the pan-cancer assay design is based on an ngs panel comprising 679 genes globally curated from leading cancer databases and in partnership with key clinical cancer researchers.
A Ratings Summary
A Quant Ranking